Can You Do a DNA Test on a Baby Before It’s Born?

Prenatal DNA testing is not only possible but widely available, and most of it no longer requires a needle near the uterus. Since the late 1990s, researchers have known that fragments of fetal DNA circulate in a pregnant person’s blood, and that discovery has transformed prenatal care. Today, a simple blood draw from the mother’s arm can reveal a range of genetic information about the baby, from chromosomal conditions to biological sex to paternity. The technology, the accuracy, and the scope of what can be tested keep expanding, but so do the questions about what the results actually mean and where the limits are.

How Fetal DNA Ends Up in the Mother’s Blood

The whole field rests on a biological quirk: the placenta sheds tiny fragments of DNA into the mother’s bloodstream. These fragments, called cell-free fetal DNA, originate from placental cells and begin appearing early in pregnancy, typically becoming reliably detectable around nine or ten weeks of gestation. After delivery, the fragments clear from the mother’s blood within hours. This rapid turnover is part of what makes the test pregnancy-specific; leftover DNA from a prior pregnancy is not a concern.

The tests built on this technology go by several names, most commonly non-invasive prenatal testing (NIPT) or non-invasive prenatal screening (NIPS). Despite the word “fetal” in “cell-free fetal DNA,” the DNA actually comes from the placenta, not the baby directly. That distinction matters when results don’t match what’s really going on with the fetus, a problem we’ll get to shortly.

Screening for Down Syndrome and Other Chromosomal Conditions

The most common reason people get prenatal DNA testing is to screen for trisomies, conditions caused by an extra copy of a chromosome. Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13) are the three most frequently screened. The accuracy is striking: a meta-analysis found pooled sensitivity of about 99% for Down syndrome, 97% for Edwards syndrome, and 97% for Patau syndrome, with specificity above 99.9% for all three.¹ A large clinical study of nearly 147,000 pregnancies found similar numbers, and performance was essentially the same whether the pregnancy was considered high-risk or low-risk beforehand.²

Those numbers are far better than older screening methods like the first-trimester combined test, which uses ultrasound measurements and blood markers and catches roughly 85–90% of Down syndrome cases with a considerably higher false-positive rate. NIPT doesn’t replace those older tools entirely, but it has significantly reduced the number of unnecessary invasive procedures.³

Finding Out the Baby’s Sex

Determining fetal sex is one of the earliest applications of cell-free DNA analysis, and it remains one of the most popular. A large meta-analysis covering more than 10,000 tests found average sensitivity around 96.6% and specificity near 98.9% for identifying fetal sex, with performance remaining consistent regardless of trimester.⁴ A separate meta-analysis reported broadly similar results, with sensitivity of about 95% and specificity of about 99%.⁵

For most families, sex determination is a matter of curiosity or nursery planning. But it has genuine medical relevance in pregnancies at risk for sex-linked genetic conditions like hemophilia or Duchenne muscular dystrophy. Knowing the fetal sex early can guide whether further invasive testing is warranted. It also raises ethical questions in regions where sex-selective pregnancy termination is a concern, a tension that professional bodies have grappled with as the test becomes cheaper and more accessible.⁶

Detecting sex chromosome aneuploidies, conditions like Turner syndrome (one X chromosome) or Klinefelter syndrome (XXY), is technically harder than simply determining male or female. Researchers have developed optimized methods that filter out noise from certain regions of the Y chromosome, reducing false-negative and false-positive rates from roughly 1% to well below 0.1%.⁷ Still, sex chromosome conditions remain an area where NIPT is less reliable than it is for the common trisomies.

Rh Factor and Blood Group Testing

One of the most medically consequential prenatal DNA tests has nothing to do with genetic disorders in the traditional sense. When an Rh-negative mother carries an Rh-positive baby, her immune system can mount an attack against the baby’s red blood cells, a condition called hemolytic disease of the fetus and newborn. For decades, all Rh-negative pregnant women received an injection of anti-D immunoglobulin as a precaution, even though roughly 40% of them were carrying Rh-negative babies and didn’t need it.

Cell-free DNA testing changed this by making it possible to determine the fetal Rh status from a maternal blood sample. A systematic review of high-throughput NIPT for fetal RhD status concluded the technology is accurate enough to substantially reduce unnecessary anti-D treatment.⁸ An earlier meta-analysis placed diagnostic accuracy at about 95%.⁹ Several countries, including Denmark, the Netherlands, and parts of the UK, have already rolled out routine fetal RhD screening for all Rh-negative pregnant women. Beyond Rh, noninvasive genotyping is extending to other blood group antigens involved in alloimmunization risk.¹⁰

Prenatal Paternity Testing

Establishing paternity before birth used to require amniocentesis, with its associated risks. Now it can be done with the same kind of maternal blood draw used for chromosome screening. Labs analyze hundreds or thousands of genetic markers called single nucleotide polymorphisms (SNPs) in the cell-free DNA and compare them against a sample from the alleged father. One validated method using 356 target SNPs achieved 100% concordance with results from amniocentesis-derived fetal DNA and generated paternity probabilities exceeding 99.9999%.¹¹

Another test using 861 SNPs, validated on over 900 samples, produced clear statistical separation between true fathers and unrelated men, with no overlap between the two groups.¹² Even in complicated cases like pregnancies affected by Down syndrome, where the extra chromosome can confuse older genetic markers, newer SNP-based methods maintain high reliability.¹³

These tests are commercially available in many countries, though they are typically ordered through a healthcare provider or an accredited lab rather than purchased off the shelf. The legal admissibility of prenatal paternity results varies by jurisdiction, so anyone needing results for a court proceeding should confirm the lab’s chain-of-custody protocols beforehand.

Screening for Single-Gene Disorders

Chromosomal conditions like Down syndrome involve large-scale changes visible across an entire chromosome. Single-gene disorders, caused by mutations in individual genes, are a trickier target. Conditions like cystic fibrosis, sickle cell disease, beta-thalassemia, and certain skeletal dysplasias can now be screened for using cell-free DNA, though the technology is newer and less thoroughly validated. One sequencing method has demonstrated the ability to analyze genes associated with more than a dozen conditions, including cystic fibrosis, beta-thalassemia, phenylketonuria, and several types of dwarfism.¹⁴

The appeal of these single-gene NIPT tests is that they can skip a logistical headache of traditional carrier screening. Carrier screening typically requires samples from both parents, and fewer than half of partners complete their testing. About 10% of cases involve misattributed paternity, which further complicates the process. Single-gene NIPT can assess fetal risk from the mother’s blood alone.¹⁵

The catch is that professional medical societies do not yet recommend single-gene NIPT for routine prenatal screening. The performance data are still limited, and false negatives are a real concern. A recent case report documented discrepant results between two different single-gene NIPT platforms for cystic fibrosis, underscoring that the technology is not yet mature enough to replace diagnostic testing for these conditions.¹⁶

When Screening Says “High Risk” and the Baby Is Fine

A persistent source of confusion and anxiety is the difference between screening and diagnosis. NIPT is a screening test. A “high-risk” result does not mean the baby definitely has a condition; it means the probability is elevated enough that diagnostic follow-up is recommended. The distinction becomes especially stark when you move beyond the common trisomies. For 22q11.2 deletion syndrome (DiGeorge syndrome), one study found a positive predictive value of only about 18%, meaning more than four out of five positive results were false alarms.¹⁷ A separate study found a similar positive predictive value of roughly 24% and a sensitivity of 75%, meaning it also missed one in four affected pregnancies.¹⁸

Why do false positives happen at all if the test is reading actual DNA? Several biological reasons. The most common is confined placental mosaicism, where the placenta has a chromosomal abnormality that the baby does not share. Remember, the DNA in the mother’s blood comes from the placenta, not the fetus directly. Other causes include a vanishing twin (an early-pregnancy twin that was affected and stopped developing, but whose DNA fragments linger), maternal mosaicism, and in rare cases, undiagnosed maternal cancers shedding abnormal DNA.¹⁹ A systematic review of discordant NIPT results identified the same core causes.²⁰

Factors That Affect Whether the Test Works Well

NIPT depends on there being enough fetal DNA in the blood sample relative to the mother’s own DNA. This proportion, called the fetal fraction, is the main technical variable. If it falls too low, the lab may issue a “no-call” or inconclusive result rather than risk an inaccurate one. A study of a Slovak population found that higher maternal BMI was associated with lower fetal fraction (correlation coefficient of −0.36), and older maternal age showed a similar trend.²¹ Gestational age also plays a role; very early blood draws, before about nine weeks, may not have enough fetal DNA to produce a reliable result.

An inconclusive result doesn’t mean something is wrong with the pregnancy. It usually means the test needs to be repeated a few weeks later when the fetal fraction has risen, or that a different screening or diagnostic approach should be considered.

Invasive Tests Still Have a Role

No matter how good screening gets, it remains screening. Confirming a chromosomal or genetic condition before birth still requires an invasive procedure: either chorionic villus sampling (CVS), typically done between 10 and 13 weeks, or amniocentesis, usually performed between 15 and 20 weeks. Both involve collecting fetal cells and analyzing them directly, producing a definitive diagnosis rather than a probability.

The historical concern with these procedures has been miscarriage risk, and that fear still shapes decision-making. But modern meta-analyses suggest the added risk is very small. A large systematic review estimated the procedure-related miscarriage risk for amniocentesis at about 0.12% and found that for CVS, when compared against control groups with similar risk profiles, the added risk was essentially zero.²² These figures are substantially lower than the one-in-two-hundred to one-in-one-hundred numbers often quoted in patient information sheets, which come from older data. A retrospective study comparing early and mid-trimester amniocentesis found procedure-related loss rates below 1% for both, with no statistically significant difference between the two timing windows.²³

In practice, NIPT serves as a gatekeeper: its high accuracy for common trisomies means far fewer people face the decision of whether to proceed with an invasive procedure. But when NIPT flags something, or when parents need answers about a condition NIPT can’t reliably screen for, amniocentesis or CVS remains the gold standard.

What Current Screening Still Misses

Even the most comprehensive commercially available NIPT panels leave substantial gaps. A cohort study examining diagnoses made after birth found that the combination of standard NIPT and carrier screening recommended by professional guidelines could have detected only about a quarter of the conditions ultimately diagnosed in the study population. Expanding to genome-wide NIPT and a larger carrier screening panel raised that figure to about 55%, which is better but still means nearly half of genetic conditions slipped through. And roughly 62% of single-gene conditions were undetectable with any current screening tool.²⁴

This is worth keeping in perspective. A normal NIPT result is reassuring for the conditions it screens for, but it is not a clean bill of genetic health. Parents and providers sometimes treat a low-risk NIPT result as if it rules out all genetic problems, which it emphatically does not.

Sequencing the Entire Fetal Genome

The technological frontier is whole-genome sequencing of a fetus from maternal blood. Researchers have already demonstrated this as a proof of concept, combining genome sequencing of both parents with deep sequencing of the cell-free DNA in maternal plasma to assemble a substantially complete fetal genome. In one study at 18.5 weeks of gestation, inherited genetic variants were predicted with about 98% accuracy, and the majority of brand-new mutations unique to the fetus were detected as well.²⁵ The researchers anticipated that further development would enable prenatal diagnosis of both recessive and dominant single-gene disorders from a blood draw alone.²⁶

This is not yet a clinical product. The cost, computational demands, and interpretive challenges are enormous. But the trajectory is clear: the amount of genetic information obtainable before birth is growing, and the barrier to accessing it is falling. That trajectory brings real benefits for families at risk of serious genetic conditions and real dilemmas for everyone involved in deciding what to do with the information.

Access and Insurance Barriers

The technology exists, but getting it covered is another matter. In the United States, insurance coverage for NIPT varies widely. A study at one medical center found that pregnant people without insurance or paying out of pocket were significantly less likely to receive genetic counseling or aneuploidy screening compared to those with either public or private insurance.²⁷ Paradoxically, having private insurance doesn’t always help. One study found that women with public insurance were more than three times as likely to have NIPT as an initial screen compared to those with private insurance, because many private plans still restrict NIPT to “high-risk” pregnancies and refuse to cover it for younger, lower-risk patients.²⁸

Out-of-pocket costs for NIPT in the US can range from a couple hundred dollars to over a thousand, depending on the lab and the insurance situation. Some labs offer cash-pay discounts that can actually undercut the insured price after copays and deductibles, so it’s worth asking about direct pricing rather than assuming the insurance route is cheapest.

The Weight of Knowing

The expanding scope of prenatal DNA testing generates information that can be genuinely difficult to interpret and act on. Genetic counselors exist specifically to help with this, but access to counseling is uneven, and the sheer volume of potential findings from newer panels can overwhelm both patients and providers.²⁹ Research into parents’ experiences has found that people value genomic information for decision-making and reassurance but often struggle to understand what expanded testing can and cannot tell them. They rely heavily on trusted healthcare professionals to interpret results, and they feel the stress of social expectations around pregnancy management.³⁰

A test result that says “low risk” is simple enough. A result that says “high risk for a condition with an 18% positive predictive value” is not. That kind of ambiguity sits in a family’s life for weeks while they decide whether to pursue invasive confirmation, and the emotional toll of that waiting period is something the accuracy statistics don’t capture.